ReviewExpert review of vaccines2009
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
Review in Expert review of vaccines, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses.Scientific reports · 2025Article
- Article
- Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.Scientific reports · 2021Article
- Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.Frontiers in immunology · 2021Article
- Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.Vaccines · 2020Review
- Next-generation influenza vaccines: opportunities and challenges.Nature reviews. Drug discovery · 2020Review
- Mouse Models Reveal Role of T-Cytotoxic and T-Reg Cells in Immune Response to Influenza: Implications for Vaccine Design.Viruses · 2019Review
- Review
- Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.PloS one · 2016Article
- Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge.mBio · 2015Article
- Ferret models of viral pathogenesis.Virology · 2015Review
- Review
- A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.The Journal of infectious diseases · 2015Article
- Advances in the development of influenza virus vaccines.Nature reviews. Drug discovery · 2015Review
- Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.Journal of virology · 2014Article
- Influenza vaccines: a moving interdisciplinary field.Viruses · 2014Review
- IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.PloS one · 2014Article
- An evaluation of the emerging vaccines against influenza in children.BMC public health · 2013Review
- Pre-existing immunity against vaccine vectors--friend or foe?Microbiology (Reading, England) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vaccinia virus of choice for preclinical and clinical studies. Owing to its avirulence and deficiency to productively replicate after in vivo inoculation, MVA can be used under biosafety level 1 conditions. In addition to a better safety profile than replication competent vaccinia viruses, the use of MVA leads to similar levels of gene expression and has better immunostimulatory properties and improved efficacy as a recombinant vaccine. In animal models, recombinant MVA vaccines were immunogenic and induced protective immunity against various infectious agents, including viruses, bacteria and parasites. Here we review the progress that has been made in the development of recombinant MVA as a viral vector and candidate pandemic influenza H5N1 vaccine. Specifically, we will focus on the preclinical evaluation of recombinant MVA vector as pandemic influenza A/H5N1 vaccine candidates and discuss the possible future approaches for the use of these novel MVA-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.